Vascular Therapies

Vascular Therapies develops a drug-device combination product for perivascular implantation during arteriovenous fistula surgeries.

Vascular Therapies (VT) is a biopharmaceutical company committed to the development and commercialization of innovative new treatments to address major unmet clinical needs of patients requiring a vascular access to support hemodialysis. Our lead product candidate, containing sirolimus, has received orphan drug designations in the U.S. and E.U. for the dialysis vascular access indications. The company consists of a focused, experienced, and passionate team driven by the goal of improving the lives of patients. We take pride in strong, global relationships with the patient, research, and medical communities. The current development plan is focused on the hemodialysis vascular access indication – investigating the safety and usefulness of the drug product to improve the outcomes of an Arterio-Venous Fistula (AVF). The company is conducting its U.S. Phase 3 randomized, AVF clinical trial in accordance with a Special Protocol Assessment (SPA) Agreement with the U.S. FDA.